Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Oncotarget|November 1, 2019
Targeting glutaminase1 and synergizing with clinical drugs achieved more promising antitumor activity on multiple myelomaQiang Qiu, Mengyuan Li, Linyu Yang, et al.Bioorganic Chemistry|August 14, 2022
SKLB-14b, a novel oral microtubule-destabilizing agent based on hydroxamic acid with potent anti-tumor and anti-multidrug resistance activitiesWanhua Zhang, Linyu Yang, Wenting Si, et al.Blood Cancer Journal|March 8, 2022
Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2<sup>V617F</sup>-induced myeloproliferative neoplasmsMengshi Hu, Tao Yang, Linyu Yang, et al.Journal of Medicinal Chemistry|October 14, 2021
Discovery of a Series of Hydroxamic Acid-Based Microtubule Destabilizing Agents with Potent Antitumor ActivityLinyu Yang, Wanhua Zhang, Qiang Qiu, et al.Journal of Medicinal Chemistry|April 3, 2019
Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous LeukemiaXue Yuan, Yong Chen, Wanhua Zhang, et al.Bioactive Materials|October 3, 2022
HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cellsQiang Qiu, Linyu Yang, Yunyu Feng, et al.Science Advances|June 17, 2021
Cevipabulin-tubulin complex reveals a novel agent binding site on α-tubulin with tubulin degradation effectJianhong Yang, Yamei Yu, Yong Li, et al.Signal Transduction and Targeted Therapy|February 28, 2023
TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTENQiang Qiu, Yuanyuan Sun, Linyu Yang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>-Induced B-Cell Acute Lymphoblastic LeukemiaLinyu Yang, Qiang Qiu, Minghai Tang, et al.Journal of Medicinal Chemistry|May 7, 2026
Identification and Optimization of Pyridone Derivatives as Pan-MEK/RAF Nondegrading Molecular Glues for the Treatment of RAS-Driven CancersPeng Wang, Yongting Yuan, Linyu Yang, et al.Pageof 6